Choroidal neovascularisation (CNV)

Prescribing Notes:

• Ranibizumab is approved for the treatment for visual impairment due to choroidal neovascularisation secondary to pathologic myopia in adults. 
• Aflibercept is approved for adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV). 
• Vascular endothelial growth factor inhibitors (ranibizumab and aflibercept) are only to be administered by specialists experienced in the management of Choroidal neovascularisation (CNV).